This is the Board to discuss the Industry. Here
are a few URLs I found
For what it is worth, some data that got ATCI the FDA approval
usaeyes.com
Now, for hyperopia (only VISX has FDA appoval) neat drawings
usaeyes.com
Ha! and the FDA has it's own consumer magazine and practically advertises laser correction ! But did you know Summit is approved for 21 year-olds and VISX for 18-year-olds ? However VISX recommends 21 year minimum also, I heard Logan say (Mar 3 interview)
usaeyes.com
A lot of news, if you really want to inform yourself.
I think some of it is more important than the TA wiggles. If you know this type of news , the wiggles may surprise you less.
Laser mfr or laser center stock? Who makes how much of the money ? Interesting for your judgement.
usaeyes.com
and LASIK was not FDA approved a year ago ? Is it now ?
usaeyes.com
More in eyeworld.org
Nidek has a website www.nidek.com but does not tell you that their FDA approval is only for myopia without astigmatism (see S-4 filing)
Who has what FDA approval is listed on page 89 of the second amendment to the S-4 filed March 24 . Very clear, VISX has the most. However, tracking would be nice to have on VISX lasers, an ophthalmologist posted on Yahoo! BEAM .....He also said, the ATCI machine is still unproven. Somebody else waits for what the “opinionmakers' say. The Ophtho pope and Cardinals, I guess.
The confusing exchange terms of how many BEAM shares and how much money will be paid for each ATCI share are spelled out in the original S-4 filing of November 1998 , after the merger agreement.
For those who asked about the BEAM / ATCI conversion terms, below is paragraph 1.6(a) from page A-2 of the original (November 98) S-4 Filing.
Basically, the way the market seems to be, 0.76 BEAM share plus $ 3 and a little change for each diluted ATCI share . There are two amendments, and more may come, to the S-4 SEC filing, downloadable from BEAMs website sum-tech.com
on the day of filing (sooner than EDGAR)
Section 1.6 Effect on Capital Stock. At the Effective Time, <PAGE> A-2
by virtue of the Merger and without any action on the part of the Parent, Merger Sub, the Company or any of their respective stockholders:
(a) Conversion of Securities. Each Share issued and outstanding immediately prior to the Effective Time (excluding any Shares to be canceled pursuant to Section 1.6(b)) shall be
converted, subject to Section 1.6(f), into the right to receive (i) the
quotient of 11,650,400 shares (the "Stock Consideration") of validly
issued, fully paid and nonassessable shares ("Parent Shares") of the
Common Stock, $0.01 par value per share, of Parent ("Parent Common Stock")
divided by the Diluted Company Common Stock (the "Per Share Stock
Consideration") and (ii) the quotient of $50,000,000 in cash less (A)
one-half of any amounts advanced to the Company by Parent after the date
hereof and (B) unless the holders of the Series I Preferred Stock shall
have converted such Series I Preferred Stock prior to the Effective Time,
any amounts that would be payable upon redemption of all shares of the
Company's Convertible Preferred Stock, Series I, $.01 par value per share
(the "Series I Preferred Stock"), that are issued or issuable as of the
date hereof, assuming redemption is made on the date on which the
Effective Time occurs in accordance with the provisions of the Company's
Articles of Incorporation or pursuant to any agreement with the holders of
Series I Preferred Stock prior to the Effective Time (the "Cash
Consideration") divided by the Diluted Company Common Stock (the "Per
Share Cash Consideration"). If the average closing price of Parent Common
Stock on The Nasdaq National Market for the five trading days ending on
the day before the date on which the Effective Time occurs (the "Average
Closing Price") is less than $4.2917, then the $50,000,000 in the previous
sentence shall be reduced to 11,650,400 multiplied by the Average Closing
Price.
"Diluted Company Common Stock" means the number of shares of Company
Common Stock outstanding at the Effective Time (the "Outstanding Company
Common Stock"), plus all shares of Company Common Stock issuable upon the
exercise or conversion of all options, warrants, convertible securities
or other rights, agreements, arrangements or other commitments of any
character pursuant to which the Company is obligated, contingently or
otherwise, to issue or sell shares of Company Common Stock (excluding the
Series I Preferred Stock and all rights to acquire the Series I Preferred
Stock) calculated by applying the treasury stock method to options,
warrants and convertible securities. |
